Open Access<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>
Author(s) -
Katsuaki Ogushi,
Makoto Chuma,
Haruki Uojima,
Hiroyoshi Hidaka,
Kazushi Numata,
Satoshi Kobayashi,
Shunji Hirose,
Nobuhiro Hattori,
Tomoaki Fujikawa,
Takahide Nakazawa,
Naohisa Wada,
Shuitirou Iwasaki,
Taito Fukushima,
Yusuke Sano,
Makoto Ueno,
Kuniyuki Kawano,
Kota Tsuruya,
Masako Shomura,
Tsunamasa Watanabe,
Kotaro Matsunaga,
Yosuke Kunishi,
Yusuke Saigusa,
Kazuhiro Irie,
Shogo Iwabuchi,
Makoto Kako,
Manabu Morimoto,
Tatehiro Kagawa,
Katsuaki Tanaka,
Shin Maeda
Publication year - 2020
Publication title -
clinical and experimental gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.113
H-Index - 30
ISSN - 1178-7023
DOI - 10.2147/ceg.s256691
Subject(s) - lenvatinib , medicine , hepatocellular carcinoma , gastroenterology , adverse effect , diarrhea , vomiting , oncology , sorafenib
To assess the safety, efcacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) and class B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).